Thomas M File.
Levofloxacin in the Treatment of Community-Acquired Pneumonia..
Pak J Chest Med Jan ;8(1):29-36.

Levofloxacin is the first fluoroquinolone with enhanced activity against Streptococcus Pneumonia to be marketed in the United States. Because it has in Vitro Activity against all the key respiratory pathogens (including drug-resistant S. pneumoniae and atypical pathogens) it is a promising new addition to our therapeutic armamentarium for community-acquired pneumonia (CAP). The once daily dosing schedule as well as the very high bioavialability offer distinct advantages regarding cost-effective management of CAP. This is a review article.

USER COMMENTS

I want to see the full text of this article, but i am unable to get it. Please Help me in this regard. thank you.
Posted by: hashir on Sep 2006

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com